• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Takeda Agrees to Divest Select OTC and Non-core Assets to Acino for Over $200 Million USD

Share:

October 21, 2019

Takeda Agrees to Divest Select OTC and Non-core Assets to Acino for Over $200 Million USD

Transaction accelerates deleveraging Agreement simplifies portfolio in Takeda’s NEMEA region

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of select over-the-counter (OTC) and prescription pharmaceutical assets in a
number of Near East, Middle East and Africa (NEMEA) countries within its Growth and Emerging Markets Business Unit to Acino for a total value in excess of $200 million USD. This is the third transaction in FY19 that furthers
Takeda’s strategy to focus on business areas core to its long-term growth and facilitate rapid deleveraging following its acquisition of Shire.

“The divestment of non-core assets sold in NEMEA represents the continued execution of our strategy to optimize our portfolio, invest in the defined core business areas, and accelerate our progress toward reaching our target
leverage ratio,” said Costa Saroukos, Chief Financial Officer, Takeda.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

While these products continue to play important roles in meeting patient needs, they are primarily outside of Takeda’s chosen business areas – Gastroenterology (GI), Rare Diseases, Plasma-Derived Therapies, Oncology and
Neuroscience – core to its global long-term growth.

“Takeda remains committed to this region, as we continue our work in accelerating access to our life-changing portfolio of innovative products to meet the needs of patients. We will do this via our commercial activities and
Takeda’s Access to Medicines program,” said Ricardo Marek, President, Growth and Emerging Markets Business Unit, Takeda. “We are confident that Acino is best positioned to provide uninterrupted access and supply of the divested
products to patients.”

Takeda intends to use the proceeds from this divestiture to reduce debt and continue to deleverage towards its target of 2.0x net debt/adjusted EBITDA over the next three to five years. Takeda is committed to rapid deleveraging driven by strong cash flow and divestiture proceeds, while also simplifying its portfolio.

Transaction Details

Takeda has agreed to sell a portfolio of approximately 30 select prescription pharmaceutical and OTC products sold in the NEMEA region to Acino, a Swiss pharmaceutical company headquartered in Zurich, with a clear focus on selected markets in the Middle East, Africa, the CIS Region, and Latin America. The following key countries are included in the agreement: Egypt, Saudi Arabia,South Africa, Turkey, Ukraine and United Arab Emirates, as well as other countries.

Under the terms of the agreement, Acino will acquire the rights, title, and interest to the products in the portfolio exclusive to these countries. It is anticipated that primarily sales and marketing professionals supporting the portfolio will transition to Acino at closing of the transaction. The parties will also enter into a multi-year manufacturing and supply agreement, under which Takeda will continue to manufacture the products on behalf of Acino.

The transaction is expected to close in Q4 FY19 (January – March 2020), subject to the satisfaction of customary closing conditions including receipt of applicable antitrust approvals. Until then, these products will continue to
be made available by Takeda.

Takeda is being advised by BofA Securities (financial advisor), White & Case (legal advisor), and Deloitte (financial consultant) in this transaction.

Source: Bloomberg

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Aurora Cannabis Completes Hempco Food and Fibre AcquisitionAurora Cannabis Completes Hempco Food and Fibre Acquisition
  • Led by Cigna Ventures, Arcadia Raises $29.5M to Expand Population Health Management PlatformLed by Cigna Ventures, Arcadia Raises $29.5M to Expand Population Health Management Platform
  • Wearable Company Oura Acquires Digital Identification Startup Proxy.Wearable Company Oura Acquires Digital Identification Startup Proxy.
  • Amwell Launches Smart TV Carepoint Device to Increase Telehealth Use in Patient RoomsAmwell Launches Smart TV Carepoint Device to Increase Telehealth Use in Patient Rooms
  • First Daytime Treatment for Obstructive Sleep Apnea Receives De Novo AuthorizationFirst Daytime Treatment for Obstructive Sleep Apnea Receives De Novo Authorization
  • The Path to Value-Based Care Through Patient EngagementThe Path to Value-Based Care Through Patient Engagement
  • Philips Launches Integrated Cybersecurity Services to Protect Connected Medical DevicesPhilips Launches Integrated Cybersecurity Services to Protect Connected Medical Devices
  • OMRON Launches Wheezescan Device for Children with AsthmaOMRON Launches Wheezescan Device for Children with Asthma

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications